We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Cost-Effective Diagnostic Review Monitor Receives FDA 510(K) Clearance

By MedImaging International staff writers
Posted on 27 Jan 2015
Image: NEC Display Solutions MD210C3 Diagnostic Review Monitor (Photo courtesy of NEC Display Solutions).
Image: NEC Display Solutions MD210C3 Diagnostic Review Monitor (Photo courtesy of NEC Display Solutions).
The monitor is intended as an affordable tool for viewing diagnostic images on the Picture Archiving and Communication System (PACS).

The 3-megapixel monitor has a 21.3-inch diagonal color Liquid Crystal Display (LCD) display, Light Emitting Diode (LED) backlighting, and a front-facing sensor for calibration of display brightness. The monitor is shipped already-calibrated to the DICOM grayscale luminance function. A power-saving feature, which also extends the lifetime of the monitor, reduces display brightness as soon as the operator leaves the station. The monitor features advanced connectivity such as a two-port USB hub, and a DisplayPort.

The MultiSync MD210C3 LCD monitor is manufactured by NEC Display Solutions of America (Itasca, IL, USA) and received 510(K) market clearance from the United States Food and Drug Administration (FDA).

Art Marshall, Product Manager at NEC Display Solutions, commented, “The MD210C3 display is the latest in a line of NEC MultiSync Medical Series diagnostic displays to receive FDA 510(K) market clearance for radiology.”

Related Links:

NEC Display Solutions of America


Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
MRI System
nanoScan MRI 3T/7T
Ultrasound Needle Guidance System
SonoSite L25
Mobile X-Ray System
K4W

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.